Venetoclax

Venetoclax (Venclexta) is a drug used to treat certain types of chronic lymphocytic leukemia (CLL). It is taken orally and works by blocking the activity of a protein called BCL-2, which helps cancer cells survive and grow. Venetoclax is often used in combination with other drugs, such as rituximab, to help reduce the number of cancer cells in the body. It is typically used for people who have not had success with other treatments, or have a certain type of CLL called 17p deletion.

Venetoclax, sold under the brand name Venclexta, is a medication used to treat certain types of leukemia and blood cancers. Here's a breakdown of its key features:

• Function: Venetoclax works by triggering apoptosis (programmed cell death) in specific cancer cells.
• Mechanism of action: It's a selective BCL-2 inhibitor. BCL-2 is a protein that helps cancer cells resist cell death. Venetoclax binds to BCL-2, blocking its function and allowing cancer cells to undergo apoptosis.
• Applications: Venetoclax is approved for various leukemia treatments, including:
  • Chronic lymphocytic leukemia (CLL)
  • Acute myeloid leukemia (AML) with a specific genetic mutation
• Administration: Usually given as tablets taken by mouth, but intravenous (IV) formulations are also available. The dosage and schedule depend on the specific condition being treated and other factors.

Here are some additional points to consider:

• Combination therapy: Venetoclax is often used in combination with other chemotherapy drugs to improve treatment outcomes.
• Potential side effects: Common side effects include low blood cell counts, which can increase the risk of infection and bleeding. Nausea, fatigue, and tumor lysis syndrome (TLS) are also potential side effects. TLS is a rapid breakdown of cancer cells that can overwhelm the body's waste disposal systems. Regular monitoring by a doctor is essential during treatment with venetoclax.
• Not a cure: Venetoclax may induce remission (reduction of disease activity), but it likely won't cure leukemia.